In summary, liver tissue from patients with advanced MASLD revealed an increased expression of genes known to cleave APP towards the non-amyloidogenic pathway, such as ADAM9, ADAM10, ADAM17, and BACE2, which are likely involved in decreased hepatic Aβ-42 levels in MASLD. Here, APP is linked to metabolic dysfunction-associated steatotic liver disease.